Birthmarks
Also known as: Congenital nevus
Methodology & AI Transparency ⓘ
Birthmarks Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Birthmarks are abnormalities of the skin that are present when a baby is born.
- 2 Real-world patient consensus: Clinical coding for Birthmarks uses ICD-10 Q82.5 across Blood Pressure specialty care.
- 3 Typical cash cost range: Clinicians assessing Birthmarks focus on elevated systemic vascular in Birthmarks (Q82.5: resistance) and targeted history.
- 4 Top reported side effects / signs: Key Blood Pressure biomarkers for Birthmarks (Q82.5): Urine Albumin-to-Creatinine Ratio [Birthmarks Q82.5] & Home Seated Blood in Birthmarks (Q82.5: Pressure) (< 120/75 mmHg (Q82.5)).
Ask our AI Specialists anything about Birthmarks
What Is Birthmarks?
Birthmarks are abnormalities of the skin that are present when a baby is born. There are two types of birthmarks. Vascular birthmarks are made up of blood vessels that haven't formed correctly. They are usually red. Two types of vascular birthmarks are hemangiomas and port-wine stains. Pigmented birthmarks are made of a cluster of pigment cells that cause color in the skin. They can be many different colors, from tan to brown, gray to black, or even blue. Moles can be birthmarks. No one knows what causes many types of birthmarks, but some run in families. Your baby's doctor will look at the birthmark to see if it needs any treatment or if it should be watched.
Pathophysiology, Underlying Causes & Clinical Presentation
Birthmarks (Q82.5) alters blood pressure homeostasis through elevated systemic vascular in Birthmarks (Q82.5: resistance); Cross-referenced with NIH MeSH (Nevus, Hemangioma), clinical remission targets Home Seated Blood in Birthmarks (Q82.5: Pressure) within < 120/75 mmHg (Q82.5).
Common Symptoms & Clinical Signs
- • Presentation of Birthmarks (Q82.5): calf cramping or in Birthmarks (Q82.5: claudication triggered by)
- • Secondary Birthmarks clinical sign: localized extremity swelling, in Birthmarks (Q82.5: warmth, or venous)
- • Symptom flares in Birthmarks correlating with Urine Albumin-to-Creatinine Ratio [Birthmarks Q82.5] deviation outside < 15 mg/g (Q82.5)
- • Functional blood pressure impact requiring duplex vascular ultrasonography [Birthmarks Q82.5] evaluation (Q82.5)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Birthmarks Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q82.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Birthmarks Q82.5] | < 15 mg/g (Q82.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Birthmarks (Q82.5: Pressure) | < 120/75 mmHg (Q82.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Birthmarks Q82.5] | 1.00 – 1.30 (Q82.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Birthmarks
Treatment selection for Birthmarks depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Birthmarks)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Randomized trials of telmisartan vs. Valsartan therapy: Which Works Better for Blood pressure reduction? When data from the single-drug treatment and combination therapy (with hydrochlorothiazide) trials were pooled separately, telmisartan therapy was associated with a statistically significant difference in BP reductions... Hypertension research : official journal of the Japanese Society of Hypertension • 2013-07-15 • Meta-Analysis | N = 5,422 | 94/100 | PMID 23344134 ↗ |
| New Insights on Heart and blood vessel risk factors and related comorbid conditions and medical: What a 746-Participant Study Found Once-daily tadalafil 5 mg improved LUTS/BPH, regardless of severity, in men with coexisting heart and blood vessel risk factors/comorbidities, except for patients with history of > 1 drug for arterial high blood pressure. International journal of clinical practice • 2015-12-15 • Randomized Controlled Trial | N = 746 | 93/100 | PMID 26299520 ↗ |
| New Insights on Pharmacogenomics of high blood pressure: a genome‐wide, placebo‐controlled: What a 386-Participant Study Found These data provide some evidence for a link between biology of the glomerular protein nephrin and blood-pressure-lowering action of angiotensin receptor antagonists and encourage additional studies on aldehyde... Journal of the American Heart Association • 2015-01-26 • Randomized Controlled Trial | N = 386 | 93/100 | PMID 25622599 ↗ |
| New Insights on Serum Vitamin A Is Associated with Variations in the Relationship between Plasma: What a 4,091-Participant Study Found The relationship between vitamin B6 indexes and AMI risk varied according to serum Vit-A concentrations. The Journal of nutrition • 2026-01-15 • Phase III Randomized Trial | N = 4,091 | 90/100 | PMID 41176280 ↗ |
| New Insights on Mild thrombocytopenia on bleeding and recurrent thrombosis in: What a 1,045-Participant Study Found Bleeding risk for edoxaban and dalteparin varied in gastrointestinal and hematologic malignances in patients with thrombocytopenia (clinicaltrails gov. Haematologica • 2024-06-01 • Phase III Randomized Trial | N = 1,045 | 90/100 | PMID 37855029 ↗ |
Birthmarks Patient Community & “People Like Me” Threads
Filter Birthmarks community threads and patient logs by age, biological sex, dosage, and treatment duration.